Endocannabinoid system involvement in brain reward processes related to drug abuse.
Marcello Solinas, Sevil Yasar, Steven R Goldberg
Pharmacological Research November 2007 DOI: 10.1016/j.phrs.2007.09.005 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Key findings | The authors argue that the endocannabinoid system is centrally involved in brain reward functions and drug abuse: cannabinoids and endocannabinoids produce rewarding effects, manipulating the system modulates the rewarding effects of other abused drugs, and most abused drugs alter brain endocannabinoid levels. They further contend the system contributes to relapse-related drug-seeking behavior in animal models, making it a promising medication target for treating drug abuse. |
Abstract
Cannabis is the most commonly abused illegal drug in the world and its main psychoactive ingredient, delta-9-tetrahydrocannabinol (THC), produces rewarding effects in humans and non-human primates. Over the last several decades, an endogenous system comprised of cannabinoid receptors, endogenous ligands for these receptors and enzymes responsible for the synthesis and degradation of these endogenous cannabinoid ligands has been discovered and partly characterized. Experimental findings strongly suggest a major involvement of the endocannabinoid system in general brain reward functions and drug abuse. First, natural and synthetic cannabinoids and endocannabinoids can produce rewarding effects in humans and laboratory animals. Second, activation or blockade of the endogenous cannabinoid system has been shown to modulate the rewarding effects of non-cannabinoid psychoactive drugs. Third, most abused drugs alter brain levels of endocannabinoids in the brain. In addition to reward functions, the endocannabinoid cannabinoid system appears to be involved in the ability of drugs and drug-related cues to reinstate drug-seeking behavior in animal models of relapse. Altogether, evidence points to the endocannadinoid system as a promising target for the development of medications for the treatment of drug abuse.
Citations in the library
Cited by 6
- Consommation de cannabis: quels sont les risques ? Annales de Toxicologie Analytique 2008
- CB1 Receptor Silencing Attenuates Ketamine-Induced Hyperlocomotion Without Compromising Its Antidepressant-Like Effects Cannabis and Cannabinoid Research October 1, 2023
- The CB1 Neutral Antagonist Tetrahydrocannabivarin Reduces Default Mode Network and Increases Executive Control Network Resting State Functional Connectivity in Healthy Volunteers. The International Journal of Neuropsychopharmacology September 10, 2015
- Involvement of the endocannabinoid system in reward processing in the human brain. Psychopharmacology February 2012
- Dopaminergic augmentation of delta-9-tetrahydrocannabinol (THC) discrimination: possible involvement of D(2)-induced formation of anandamide. Psychopharmacology April 2010
and 1 more in the library
Cites 19
- Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis Proceedings of the National Academy of Sciences December 13, 2005
- Nicotinic facilitation of delta9-tetrahydrocannabinol discrimination involves endogenous anandamide. Journal of Pharmacology and Experimental Therapeutics June 2007
- The endogenous cannabinoid anandamide produces delta-9-tetrahydrocannabinol-like discriminative and neurochemical effects that are enhanced by inhibition of fatty acid amide hydrolase but not by inhibition of anandamide transport. Journal of Pharmacology and Experimental Therapeutics April 2007
- SR 141716A differentially attenuates the behavioral effects of delta9-THC in rhesus monkeys. Behavioural Pharmacology September 2005
- Involvement of mu-, delta- and kappa-opioid receptor subtypes in the discriminative-stimulus effects of delta-9-tetrahydrocannabinol (THC) in rats. Psychopharmacology June 2005
and 14 more in the library